PhaseRx is developing a portfolio of mRNA products to treat children with life-threatening inherited liver diseases, and expects to achieve clinical proof of concept in patients with an approvable end point in 2018.
PhaseRx is a biopharmaceutical company developing a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. PhaseRx expert scientists are passionately committed to making a positive social impact by reducing serious medical problems and fatalities caused by these rare diseases.
410 West Harrison Street
Seattle WA 98119